Ozempic Cost in South Dakota (2026): Prices, Insurance, and Savings Options

What Does Ozempic Actually Cost in South Dakota?

The cash-pay price for Ozempic across South Dakota retail pharmacies averages $998 per month in 2026, matching the Novo Nordisk list price. That figure applies to all four dose tiers (0.25 mg through 2.0 mg) because each pen contains a one-month supply regardless of dose. Prices at independent pharmacies in Sioux Falls, Rapid City, and Aberdeen fall within a narrow band because wholesale acquisition cost sets the floor.

Retail Pharmacy Pricing

South Dakota has roughly 200 retail pharmacies. Most stock Ozempic, but pricing varies by less than $30 across chains. Walmart, Walgreens, and Lewis Drug locations typically list between $975 and $1,010 for a single pen without insurance. GoodRx and similar discount aggregators can shave 2% to 5% off, but the savings are modest on a brand-name biologic with no generic equivalent.

How the Price Compares Nationally

South Dakota's cash-pay price tracks the national average almost exactly. The FDA-approved prescribing information for Ozempic does not dictate retail pricing, but Novo Nordisk's wholesale acquisition cost of $935.77 per pen sets a consistent baseline across states [1]. Rural pharmacies sometimes add a small dispensing markup, so patients in western South Dakota may see prices $10 to $20 higher than Sioux Falls metro pharmacies.

Does South Dakota Medicaid Cover Ozempic?

South Dakota Medicaid does not cover Ozempic as of May 2026. The state's preferred drug list excludes semaglutide injection for both type 2 diabetes and weight management indications. This means Medicaid enrollees cannot obtain Ozempic through their plan, even with prior authorization.

Why Medicaid Excludes It

South Dakota expanded Medicaid in 2023 following a ballot initiative, adding roughly 52,000 new enrollees according to South Dakota Department of Social Services data. The state's Medicaid pharmacy benefit uses a restrictive formulary to control per-member costs. GLP-1 receptor agonists carry high acquisition costs, and South Dakota's Medicaid program has opted for older, less expensive diabetes therapies as first-line agents [2].

Alternatives for Medicaid Patients

Medicaid-enrolled patients with type 2 diabetes may have access to metformin, sulfonylureas, or certain insulin formulations through the preferred drug list. For patients whose clinicians believe semaglutide is medically necessary, a formal exception request can be submitted. Approval rates for these exceptions remain low, running below 15% based on similar state Medicaid audit reports published by the Centers for Medicare and Medicaid Services [3].

Insurance Coverage for Ozempic in South Dakota

Commercial insurance plans in South Dakota vary widely in their coverage of Ozempic. Large employers and national carriers like Blue Cross Blue Shield of South Dakota, Sanford Health Plan, and Avera Health Plans each maintain their own formulary tiers and prior authorization requirements.

Commercial Plan Tiers

Most commercial plans that do cover Ozempic place it on a specialty or non-preferred brand tier, which means copays between $75 and $250 per fill after deductible. Plans with no GLP-1 coverage require full cash-pay pricing. The key variable is whether the plan covers Ozempic for type 2 diabetes only or also extends coverage for off-label weight management. The American Diabetes Association Standards of Care recommend GLP-1 receptor agonists as second-line therapy after metformin for patients with type 2 diabetes who have established cardiovascular disease or high cardiovascular risk [4].

How to Check Your Coverage

Call the number on the back of your insurance card and ask three questions: Is semaglutide injection (Ozempic) on the formulary? What tier? Is prior authorization required? If your plan denies coverage, your prescriber can submit a formulary exception using clinical documentation such as HbA1c history and prior medication trials.

Medicare Part D

Medicare Part D plans in South Dakota may cover Ozempic for type 2 diabetes but not for weight loss. Copay amounts depend on the specific Part D plan and which coverage phase the patient has reached. The Inflation Reduction Act's $2,000 annual out-of-pocket cap, fully effective in 2025, limits total Part D spending for beneficiaries, which can reduce Ozempic costs significantly for Medicare enrollees [5].

The Novo Nordisk Savings Card

Novo Nordisk offers a manufacturer savings card for Ozempic that reduces out-of-pocket cost to as low as $25 per 1-month, 2-month, or 3-month prescription fill. The card is available to patients with commercial insurance and covers up to $150 per fill for a maximum of 24 months.

Eligibility Rules

The savings card excludes patients enrolled in Medicare, Medicaid, TRICARE, or any other federal or state government-funded program. Patients must have commercial insurance with Ozempic on the formulary. Uninsured patients do not qualify for the savings card but may qualify for the Novo Nordisk Patient Assistance Program (PAP), which provides Ozempic at no cost to qualifying low-income patients [1].

How to Activate It

Patients can download the card from the Novo Nordisk website or receive one from their prescriber's office. The card is presented to the pharmacist at the point of sale alongside the insurance card. No separate application or income verification is needed for the savings card (the PAP does require income documentation).

Compounded Semaglutide in South Dakota

Compounded semaglutide is available in South Dakota through licensed 503A compounding pharmacies. These pharmacies produce patient-specific preparations of semaglutide at a typical cost of $199 per month, roughly 80% less than brand-name Ozempic.

Legal Status

The FDA has placed semaglutide on and off the drug shortage list multiple times since 2022. As of early 2026, compounding pharmacies operating under Section 503A of the Federal Food, Drug, and Cosmetic Act can legally compound semaglutide when the drug is on the shortage list, or when a prescriber documents a clinical need for a patient-specific formulation (such as an alternative concentration or preservative-free preparation). South Dakota does not impose additional state-level restrictions beyond federal 503A requirements [6].

Quality Considerations

Compounded medications are not FDA-approved and do not undergo the same manufacturing oversight as branded products. The FDA has issued warnings about adverse events linked to improperly compounded semaglutide, including dosing errors and sterility failures [6]. Patients considering compounded semaglutide should verify that the pharmacy holds current state licensure and follows United States Pharmacopeia (USP) 797 sterile compounding standards.

How It Compares Clinically

No head-to-head trials compare compounded semaglutide to brand-name Ozempic. The SUSTAIN clinical trial program established the efficacy of Novo Nordisk's formulation specifically. In SUSTAIN-7 (N=1,201), semaglutide 0.5 mg reduced HbA1c by 1.5% and body weight by 4.6 kg at 40 weeks, while semaglutide 1.0 mg reduced HbA1c by 1.8% and body weight by 6.5 kg versus dulaglutide [7]. These results apply to the branded formulation. Compounded versions use the same active molecule but may differ in excipients, concentration, and stability.

Telehealth Access to Ozempic in South Dakota

South Dakota permits telehealth prescribing of Ozempic with no in-person visit requirement. The state's telehealth parity law, updated in 2021, allows licensed prescribers to evaluate patients and issue prescriptions for controlled and non-controlled medications via synchronous video or audio visits.

How It Works

A patient schedules a video consultation with a licensed prescriber (physician, nurse practitioner, or physician assistant) through a telehealth platform. The prescriber reviews medical history, orders labs if needed, and sends the prescription to a pharmacy of the patient's choice. South Dakota requires that the prescribing clinician hold an active South Dakota medical license or practice under a valid interstate compact.

Telehealth and Compounded Semaglutide

Many telehealth platforms that prescribe semaglutide partner directly with 503A compounding pharmacies, offering bundled pricing that includes the consultation, prescription, and medication shipped to the patient's door. These bundles typically run $250 to $350 per month total. Patients should confirm that the prescribing clinician is licensed in South Dakota and that the compounding pharmacy ships to the state.

Cost-Reduction Strategies for South Dakota Patients

Several approaches can lower the effective cost of Ozempic or semaglutide therapy for South Dakota residents. The right strategy depends on insurance status, income, and clinical indication.

For Commercially Insured Patients

Use the Novo Nordisk savings card to bring copays down to $25 per fill. If your plan does not cover Ozempic, ask your prescriber to submit a prior authorization with supporting clinical documentation. The Endocrine Society Clinical Practice Guideline on pharmacological management of obesity supports GLP-1 receptor agonist use in patients with BMI ≥30 or BMI ≥27 with at least one weight-related comorbidity, which can strengthen an appeal [8].

Dr. Robert Gabbay, Chief Scientific and Medical Officer of the American Diabetes Association, has stated: "Access to GLP-1 receptor agonists should not be determined by geography or insurance status. These medications have transformed outcomes for people living with type 2 diabetes" [4].

For Uninsured Patients

Apply for the Novo Nordisk Patient Assistance Program, which provides Ozempic free of charge to patients with household income at or below 400% of the federal poverty level. Alternatively, compounded semaglutide at $199 per month through a licensed 503A pharmacy represents the lowest-cost option for most uninsured patients.

For Medicare Beneficiaries

The $2,000 annual Part D out-of-pocket cap means that even at list price, total annual spending on Ozempic is capped. Patients who reach the cap early in the year pay $0 for the remainder. Timing initial fills in January can maximize the months of zero-cost coverage.

Pharmacy Shopping

Prices across South Dakota pharmacies differ by small margins, but mail-order pharmacies and some 340B-eligible facilities can offer lower pricing. Federally Qualified Health Centers in South Dakota participate in the 340B program and may dispense Ozempic at reduced cost to qualifying patients.

Clinical Context: Why Ozempic Is Prescribed

Ozempic (semaglutide) is a GLP-1 receptor agonist approved by the FDA in December 2017 for the treatment of type 2 diabetes in adults. It is administered as a once-weekly subcutaneous injection and is available in 0.25 mg, 0.5 mg, 1.0 mg, and 2.0 mg doses [1].

Efficacy Data

The SUSTAIN trial program evaluated semaglutide across multiple patient populations. In SUSTAIN-7, semaglutide 1.0 mg produced significantly greater HbA1c reductions (1.8% vs. 1.4%) and weight loss (6.5 kg vs. 3.0 kg) compared to dulaglutide 1.5 mg over 40 weeks [7]. The SELECT trial (N=17,604) demonstrated that semaglutide 2.4 mg reduced major adverse cardiovascular events by 20% in adults with overweight or obesity and established cardiovascular disease, without diabetes, over a median follow-up of 39.8 months [9].

The 2024 ADA Standards of Care note: "In patients with type 2 diabetes and established atherosclerotic cardiovascular disease, a GLP-1 receptor agonist with proven cardiovascular benefit is recommended, independent of baseline HbA1c or individualized HbA1c target" [4].

Dose Titration

Patients start at 0.25 mg weekly for four weeks, then increase to 0.5 mg. Based on glycemic response, the dose may be increased to 1.0 mg after at least four weeks, and then to 2.0 mg after another four weeks. Nausea, the most common side effect, tends to diminish with gradual titration. In SUSTAIN trials, nausea occurred in 15% to 20% of patients on semaglutide versus 6% to 10% on comparators [7].

South Dakota-Specific Considerations

South Dakota's rural geography creates unique access challenges. Roughly 45% of the state's population lives in rural areas, according to U.S. Census Bureau data, and specialty pharmacies may be hours away from many communities [10].

Rural Access

Telehealth prescribing and mail-order pharmacy fulfillment bridge the distance gap. Patients in rural western South Dakota can receive Ozempic or compounded semaglutide by mail with standard cold-chain shipping. Most telehealth platforms include shipping costs in their bundled pricing.

State Regulatory Environment

South Dakota's Board of Pharmacy oversees compounding pharmacy licensure within the state. Out-of-state 503A pharmacies shipping into South Dakota must hold a non-resident pharmacy license. Patients should verify this licensure before ordering from any out-of-state compounder.

South Dakota does not impose state-level step therapy requirements on commercial insurance plans for GLP-1 receptor agonists, though individual insurers may apply their own step therapy protocols requiring metformin trial before approving semaglutide coverage.